ArticleCell host & microbe2016
Tackling Difficult Staphylococcus aureus Infections: Antibodies Show the Way.
Article in Cell host & microbe, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 29 citations in OpenAlex.
- Review
- Microbiota and metabolic adaptation shapebioRxiv : the preprint server for biology · 2024Article
- Antibody-Antibiotic Conjugates: A Comprehensive Review on Their Therapeutic Potentials Against BacterialInfections.Journal of clinical laboratory analysis · 2024Review
- Necrotizing Pneumonia in Children: Early Recognition and Management.Journal of clinical medicine · 2023Review
- Article
- A single center experience of intravenous immunoglobulin treatment in Covid-19.International immunopharmacology · 2021Observational
- Antibiotic Combined with Epitope-Specific Monoclonal Antibody Cocktail Protects Mice Against Bacteremia and Acute Pneumonia from Methicillin-ResistantJournal of inflammation research · 2021Article
- Importance of immunoglobulin therapy for COVID-19 patients with lymphocytopenia.Bulletin of the National Research Centre · 2021Review
- Macrocycle-Antibiotic Hybrids: A Path to Clinical Candidates.Frontiers in chemistry · 2021Review
- COVID-19: benefits and risks of passive immunotherapeutics.Human vaccines & immunotherapeutics · 2020Review
- Adjunct Immunotherapies for the Management of Severely Ill COVID-19 Patients.Cell reports. Medicine · 2020Review
- Natural Antibodies: from First-Line Defense Against Pathogens to Perpetual Immune Homeostasis.Clinical reviews in allergy & immunology · 2020Review
- Could Intravenous Immunoglobulin Collected from Recovered Coronavirus Patients Protect against COVID-19 and Strengthen the Immune System of New Patients?International journal of molecular sciences · 2020Article
- Intravenous Immunoglobulin Therapy EliminatesInternational journal of molecular sciences · 2019Article
- Impact of Bacterial Membrane Fatty Acid Composition on the Failure of Daptomycin To Kill Staphylococcus aureus.Antimicrobial agents and chemotherapy · 2018Article
- Human Memory B Cells TargetingmBio · 2018Article
- Monomeric Immunoglobulin A from Plasma Inhibits Human Th17 ResponsesFrontiers in immunology · 2017Article
Corrections and comments
- Comment on
- Comment on
Authors and funding
3 authors at 2 institutions in 2 countries.
Funding
Abstract
The recent spread of community-acquired methicillin-resistant Staphylococcus aureus (MRSA) has brought increasing concerns of heightened disease severity and persistence following invasive disease. In line with the need for new treatment paradigms, two recent reports have shown that antibody-based therapies can restrict acute S. aureus infection and persistence and improve pathological symptoms.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.